

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



New Ray Medicine  
新銳醫藥

## **New Ray Medicine International Holding Limited**

**新銳醫藥國際控股有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 6108)**

### **POLL RESULTS OF THE SPECIAL GENERAL MEETING HELD ON 16 JULY 2024**

The Resolution as set out in the Notice was duly passed by way of a poll at the SGM held on Tuesday, 16 July 2024.

Reference is made to the circular (“**Circular**”) of New Ray Medicine International Holding Limited (“**Company**”) dated 21 June 2024 and notice (“**Notice**”) of the special general meeting (“**SGM**”) dated 21 June 2024. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in this Circular.

The Board is pleased to announce that the resolution as set out in the Notice (“**Resolution**”) was duly passed by the Shareholders by way of a poll at the SGM.

As at the date of the SGM, there were a total of 1,671,846,657 Shares in issue, and the Company did not hold any treasury shares (including any treasury shares held or deposited with the Central Clearing and Settlement System). To the best of the Directors’ knowledge, information and belief having made all reasonable enquiries, no Shareholder was required to abstain from voting on the resolution proposed at the SGM. As such, there were a total of 1,671,846,657 Shares, representing 100% of the Shares in issue as at the date of the SGM, entitling the Shareholders to attend and vote on the resolution proposed at the SGM. None of the Shareholders was entitled to attend and abstain from voting in favour of the resolution proposed at the SGM according to Rule 13.40 of the Listing Rules. No Shareholder is required under the Listing Rules to abstain from voting. None of the Shareholders have stated their intention in the Circular to vote against the resolution proposed or to abstain from voting at the SGM.

ORDINARY RESOLUTION	Number of votes and percentage	
	For	Against
To approve the Sale and Purchase Agreement and to approve the transactions contemplated thereunder and to authorise any one of the directors of the Company to take all such actions as he/she considers necessary, appropriate, desirable and expedient for the purposes of giving effect to or in connection with the Sale and Purchase Agreement and all transactions contemplated thereunder.	429,438,400 (100.00%)	0 (0.00%)

*Note:* The number of votes and percentage of the voting as stated above are based on the total number of Shares held by the Shareholders who attended and voted at the SGM in person, by authorised corporate representative or by proxy.

All Directors attended the SGM in person or via electronic means.

As more than 50% of the votes were cast in favour of the Resolution, the Resolution was duly passed by the Shareholders as an ordinary resolution of the Company.

The Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, acted as the scrutineer for the vote-taking at the SGM.

On behalf of the Board  
**New Ray Medicine International Holding Limited**  
**Wang Qiuqin**  
*Chairman, Chief Executive Officer and Executive Director*

Hong Kong, 16 July 2024

*As at the date of this announcement, the executive Directors are Ms. Wang Qiuqin, Mr. Huo Zhihong, Mr. Chu Xueping and Ms. Zhou Wan; and the independent non-executive Directors are Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.*